All In Biotech

Drug Trial Radar · NCT07879885

An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants With Moderate-to-severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

390

Planned (sponsor's estimate)

Start

Jul 31, 2025

Primary completion

Mar 1, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Oct 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

Conditions

  • Moderate-to-severe Plaque Psoriasis

Interventions

  • HS-20137Biological

    HS-20137 200 mg injection at weeks 0, 4 and 8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: up to 20 weeks
  2. Changes From Baseline in Clinical Laboratory Test ResultsTime frame: Frame: up to 20 weeks
  3. Changes From Baseline in Physical Examination FindingsTime frame: up to 20 weeks
  4. Changes From Baseline in Vital SignsTime frame: up to 20 weeks
  5. Incidence of Clinically Significant Electrocardiogram (ECG) AbnormalitiesTime frame: up to 20 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijng, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.